ALPS Advisors’s Ventyx Biosciences VTYX Stock Holding History

ALPS Advisors’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-43,437	Closed	-$1.51M	–	1016
2023 Q3	$1.51M	Buy	43,437 +393	+0.9%	+$13.6K	0.01%	368
2023 Q2	$1.41M	Buy	43,044 +5,727	+15%	+$197K	0.01%	387
2023 Q1	$1.25M	Sell	37,317 -1,074	-3%	-$41.8K	0.01%	400
2022 Q4	$1.26M	Buy	+38,391	New	+$1.14M	0.01%	400

Other funds holding VTYX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

ALPS Advisors's VTYX Position: Q4 2023 in Review

ALPS Advisors sold out of Ventyx Biosciences (VTYX) in Q4 2023, closing a stake of 43,437 shares — an estimated $1.51M sold.

ALPS Advisors first reported a position in VTYX in Q4 2022 and held it in 4 quarters. The position peaked at $1.51M in Q3 2023. 121 funds tracked by Wall St. Rank hold VTYX as of Q4 2023.

ALPS Advisors reported no remaining Ventyx Biosciences position as of Q4 2023 after selling out during the quarter.
ALPS Advisors sold 43,437 Ventyx Biosciences shares in Q4 2023, an estimated $1.51M.
ALPS Advisors first reported a position in Ventyx Biosciences in Q4 2022 and held it in 4 quarters.
ALPS Advisors's Ventyx Biosciences position peaked at $1.51M in Q3 2023.
121 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2023.

Based on ALPS Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.